Faculty Profiles - NAGAO Shoji

Papers - NAGAO Shoji

Division display 1 - 20 of about 128 ／ All the affair displays >>

Epithelioid trophoblastic tumor diagnosed during a thorough examination of recurrent implantation failure: A case report

Yasuhiko Kamada, Junko Haraga, Naoyuki Ida, Shoji Nagao, Hiroyuki Yanai, Hisashi Masuyama

Journal of Obstetrics and Gynaecology Research 2025.3

Incidence and risk factors for venous thromboembolism in gynecological cancer: the GOTIC-VTE trial. International journal

Yoshifumi Takahashi, Hiroyuki Fujiwara, Kouji Yamamoto, Satoshi Yamaguchi, Shoji Nagao, Masashi Takano, Morikazu Miyamoto, Kosei Hasegawa, Maiko Miwa, Toshiaki Yasuoka, Soichi Yamashita, Takashi Hirakawa, Tomonori Nagai, Yoshinobu Hamada, Masaya Uno, Mayuyo Mori-Uchino, Michitaka Ohwada, Akira Mitsuhashi, Toyomi Satoh, Keiichi Fujiwara, Mitsuaki Suzuki

Journal of thrombosis and thrombolysis 2024.11

Language：English Publishing type：Research paper (scientific journal)

Real-world data on venous thromboembolism (VTE) in Japanese patients with gynecological cancer are lacking. The GOTIC-VTE trial aimed to evaluate the frequency of VTE-associated events and risk factors at the time of cancer diagnosis and during 1-year follow-up. From July 2017 to February 2019, patients with endometrial, cervical, ovarian, tubal, or peritoneal cancer who underwent VTE screening within 2 months before registration, were enrolled. Of the 1008 patients enrolled, 881 were included in the analysis set, 51 (5.8%) had VTE at the time of cancer diagnosis (baseline), 7 (0.8%) had symptomatic VTE, and the majority had asymptomatic VTE (n = 44; 5.0%). Patients with ovarian, tubal, or peritoneal cancer had a higher incidence of VTE (13.7%) than those with other cancer types. During the 1-year follow-up, 0.9% (n = 8) of the patients had symptomatic VTE, 3.5% (n = 31) had composite VTE (symptomatic VTE and incidental VTE requiring treatment), 0.2% (n = 2) had bleeding events, and 4.3% (n = 38) had all-cause death, all of which were significantly higher in the VTE group at baseline. In the multivariate analysis, chemotherapy was an independent risk factor for composite VTE during the 1-year follow-up (hazard ratio 3.85, 95% confidence interval 1.39-13.63, p = 0.018). Among gynecological cancers, VTE incidence is particularly high in ovarian, tubal, or peritoneal cancer, and patients undergoing chemotherapy should be cautioned against VTE occurrence during treatment.The GOTIC-VTE trial Unique identifier, jRCTs031180124; Registration date, April 06, 2017.

DOI： 10.1007/s11239-024-03055-1

PubMed

researchmap

当院で施行した婦人科癌のがん遺伝子パネル検査の実施状況と課題

依田尚之, 長尾昌二, 谷岡桃子, 杉原花子, 谷佳紀, 白河伸介, 松岡敬典, 原賀順子, 小川千加子, 中村圭一郎, 増山寿, 平沢晃

日本癌治療学会学術集会抄録集 62回 P54 - 1 2024.10

Re-administration of platinum-based chemotherapy for recurrent endometrial cancer: an ancillary analysis of the SGSG-012/GOTIC-004/Intergroup study.

Shoji Nagao, Shin Nishio, Kazuhiro Takehara, Shinya Sato, Toyomi Satoh, Muneaki Shimada, Satoshi Yamaguchi, Hiroshi Tanabe, Masashi Takano, Kouji Horie, Yuji Takei, Yuichi Imai, Yumi Hibino, Kosei Hasegawa, Munetaka Takekuma, Kazuto Nakamura, Hirokuni Takano, Keiichi Fujiwara, Hisashi Masuyama

International journal of clinical oncology 2024.7

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: We previously demonstrated the applicability of the concept of "platinum sensitivity" in recurrent endometrial cancer. Although immune checkpoint inhibitors have been widely incorporated into endometrial cancer treatment, the debate continues regarding treatment options in patients with recurrent endometrial cancer who have previously received platinum-based chemotherapy. In this study, we assessed the duration of response to secondary platinum-based treatment using pooled data from the SGSG-012/GOTIC-004/Intergroup study. METHODS: Among the 279 participants in the SGSG-012/GOTIC-004/Intergroup study wherein platinum-based chemotherapy was re-administered for managing recurrent endometrial cancer between January 2005 and December 2009, 130 (47%) responded to chemotherapy. We compared the relationship between platinum-free interval and duration of secondary platinum-based treatment using pooled data. RESULTS: In 40 patients (31%), the duration of response to secondary platinum-based treatment exceeded the platinum-free interval. The duration of response to secondary platinum-based treatment exceeded 12 months in 51 patients (39%) [platinum-free interval: < 12 months, 14/48 (29%); 12-23 months, 18/43 (42%); 24-35 months, 8/19 (42%); ≥ 36 months, 11/20 (55%)]. In particular, in eight patients (6%), the duration of response to secondary platinum-based treatment exceeded 36 months [platinum-free interval: < 12 months, 3/48 (6%); 12-23 months, 0/19 (0%); 24-35 months, 2/19 (11%); ≥ 36 months, 3/20 (15%)]. CONCLUSIONS: Re-administration of platinum-based chemotherapy for recurrent endometrial cancer may result in a long-term response exceeding the platinum-free interval in some patients. Even in the current situation, where immune checkpoint inhibitors have been introduced, re-administration of platinum-based chemotherapy is worth considering.

DOI： 10.1007/s10147-024-02585-1

PubMed

researchmap

再発子宮体癌に対するプラチナ製剤再投与 SGSG012/GOTIC004研究追加報告

長尾昌二, 西尾真, 竹原和宏, 佐藤慎也, 佐藤豊実, 島田宗昭, 山口聡, 田部宏, 高野政志, 堀江弘二, 藤原寛行, 宮城悦子, 日比野佑美, 長谷川幸清, 武隈宗孝, 中村和人, 高野浩邦, 藤原恵一, 増山寿

日本婦人科腫瘍学会学術講演会プログラム・抄録集 66回 254 - 254 2024.7

婦人科悪性手術後のアセトアミノフェン定期静脈投与に関する検討

原賀順子, 杉原花子, 谷佳紀, 白河伸介, 入江恭平, 依田尚之, 松岡敬典, 小川千加子, 鎌田泰彦, 中村圭一郎, 長尾昌二, 増山寿

日本婦人科腫瘍学会学術講演会プログラム・抄録集 66回 391 - 391 2024.7

不妊治療中に子宮内膜異型増殖症・子宮体がんと診断され妊孕性温存治療後に生児を得た2例

鎌田泰彦, 杉原花子, 谷佳紀, 白河伸介, 入江恭平, 依田尚之, 松岡敬典, 原賀順子, 光井崇, 小川千加子, 中村圭一郎, 長尾昌二, 増山寿

日本婦人科腫瘍学会学術講演会プログラム・抄録集 66回 371 - 371 2024.7

進行上皮性卵巣癌に対する超音波ガイド下針生検

杉原花子, 谷佳紀, 白河伸介, 入江恭平, 依田尚之, 松岡敬典, 原賀順子, 小川千加子, 鎌田泰彦, 中村圭一郎, 長尾昌二, 増山寿

日本婦人科腫瘍学会学術講演会プログラム・抄録集 66回 415 - 415 2024.7

婦人科悪性手術後のアセトアミノフェン定期静脈投与に関する検討

原賀順子, 杉原花子, 谷佳紀, 白河伸介, 入江恭平, 依田尚之, 松岡敬典, 小川千加子, 鎌田泰彦, 中村圭一郎, 長尾昌二, 増山寿

日本婦人科腫瘍学会学術講演会プログラム・抄録集 66回 391 - 391 2024.7

化学療法施行中の貧血に対する静注鉄剤製剤投与に関する検討

松岡敬典, 杉原花子, 谷佳紀, 白河伸介, 入江恭平, 依田尚之, 原賀順子, 小川千加子, 鎌田泰彦, 中村圭一郎, 長尾昌二, 増山寿

日本婦人科腫瘍学会学術講演会プログラム・抄録集 66回 427 - 427 2024.7

がん対策基本法前後での離職状況の検討

谷佳紀, 中村圭一郎, 杉原花子, 白河伸介, 入江恭平, 松岡敬典, 依田尚之, 原賀順子, 小川千加子, 鎌田泰彦, 長尾昌二, 増山寿

日本婦人科腫瘍学会学術講演会プログラム・抄録集 66回 324 - 324 2024.7

当科におけるリスク低減卵管卵巣摘出術後の女性ヘルスケアについての検討

川口優里香, 小川千加子, 杉原花子, 谷佳紀, 白河伸介, 入江恭平, 松岡敬典, 依田尚之, 原賀順子, 中村圭一郎, 長尾昌二, 増山寿

現代産婦人科 72 ( 2 ) 239 - 244 2024.6

Language：Japanese Publisher：中国四国産科婦人科学会

【目的】遺伝性乳癌卵巣癌(Hereditary Brest and Ovarian Cancer:HBOC)では,卵巣癌未発症者の場合,リスク低減卵管卵巣摘出術(risk reducing salpingo-oophorectomy:RRSO)が唯一の卵巣癌予防法であり,通常35～40歳で出産完了時に行うことが推奨されている。そのため,至適時期でのRRSOは,外科的閉経を招き女性ヘルスケアに影響を与える。今回我々は,当院でRRSOを行った患者の現状と今後のヘルスケアにおけるマネジメントについて検討し,課題を抽出した。【方法】2016年4月～2023年9月にRRSOを施行された66例について,年齢,BRCA1/2バリアント,乳癌既往と治療,閉経の有無,術後更年期症状の有無,女性ヘルスケアの検査と治療などの診療情報を診療録より抽出し,検討した。【成績】RRSO実施時の年齢中央値は49歳,既閉経例は48/66例(73%)であった。7例でRRSO以前に乳癌への抗癌剤治療により早発閉経をきたしていた。術後更年期症状は,閉経患者の6/48例(12%),未閉経患者の8/18例(44%)に認めたが性機能障害などに踏み込めた問診は行われていなかった。更年期症状に対して8例で漢方療法やサプリメントなどの非ホルモン療法が,2例でホルモン補充療法(Hormone Replacement Therapy:HRT)が使用された。術後骨粗鬆症検査は16例で行われ,4例で薬物療法を要した。この4例はいずれも乳癌治療により閉経をした症例で,閉経年齢中央値は39.5歳であった。【結論】本邦のRRSO症例の多くは乳癌治療やそれに伴う閉経を経験しており,潜在的に女性ヘルスケアを必要としているが,その提供は未だ不十分である。適切に女性ヘルスケアを提供するためのシステムづくりが今後の課題と考えられた。(著者抄録)

researchmap

腫瘍の自然脱落により診断に至った子宮腺肉腫の一例

田中佑衣, 依田尚之, 白河伸介, 岡本和浩, 松岡敬典, 原賀順子, 小川千加子, 中村圭一郎, 長尾昌二, 増山寿

現代産婦人科 72 ( 2 ) 333 - 336 2024.6

Language：Japanese Publisher：中国四国産科婦人科学会

子宮腺肉腫は良性上皮性成分と肉腫成分から構成される上皮性・間葉性混合腫瘍で,子宮悪性腫瘍の約0.5%未満,肉腫の約5%を占める稀な疾患である。今回,我々は自然脱落した腫瘍組織から診断に至った子宮腺肉腫の一例を経験したので報告する。症例は69歳,2妊2産。不正性器出血を主訴に前医を受診し,子宮内膜ポリープの腟内脱出が疑われた。子宮内膜組織診で悪性所見を認めなかったが,MRIにて子宮体癌の可能性を指摘され,当科紹介となった。初診2日後,自宅にて中等量の性器出血と腟外への腫瘤の脱出を認め,緊急入院となった。入院中に手拳大の暗赤色腫瘤が自然脱落し,病理組織検査にて凝固壊死を伴う子宮腺肉腫と診断した。子宮腺肉腫IA期相当に対して腹式単純子宮全摘出術,両側付属器摘出術を施行し,術後病理学的診断は子宮腺肉腫IA期(pT1aNX)であった。術後補助療法は行わず,外来にて定期検診を施行しているが明らかな再発を認めない。子宮腺肉腫は主症状として不正性器出血を認めるが,術前の画像診断や組織診の正診率は低く,良性疾患との鑑別が困難である。不正性器出血や子宮口からの腫瘤脱出を伴う再発性のポリープ様病変を認めた際は,本疾患を鑑別に挙げることが重要である。(著者抄録)

researchmap

当科におけるリスク低減卵管卵巣摘出術後の女性ヘルスケアについての検討

川口優里香, 小川千加子, 杉原花子, 谷佳紀, 白河伸介, 入江恭平, 松岡敬典, 依田尚之, 原賀順子, 中村圭一郎, 長尾昌二, 増山寿

現代産婦人科 72 ( 2 ) 239 - 244 2024.6

Language：Japanese Publisher：中国四国産科婦人科学会

researchmap

HBOCに対するリスク低減卵管卵巣摘出術及び乳腺外科手術の合同実施に関する当院での取り組み

花谷智美, 原賀順子, 小川千加子, 長尾昌二, 杉原花子, 谷佳紀, 白河伸介, 依田尚之, 松岡敬典, 中村圭一郎, 平沢晃, 増山寿

日本産科婦人科学会雑誌 76 ( 臨増 ) S - 500 2024.2

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

Ana Oaknin, Laurence Gladieff, Jerónimo Martínez-García, Guillermo Villacampa, Munetaka Takekuma, Ugo De Giorgi, Kristina Lindemann, Linn Woelber, Nicoletta Colombo, Linda Duska, Alexandra Leary, Ana Godoy-Ortiz, Shin Nishio, Antoine Angelergues, Maria Jesús Rubio, Lorena Fariñas-Madrid, Satoshi Yamaguchi, Domenica Lorusso, Isabelle Ray-Coquard, Luis Manso, Florence Joly, Jesús Alarcón, Philippe Follana, Ignacio Romero, Coriolan Lebreton, J. Alejandro Pérez-Fidalgo, Mayu Yunokawa, Hanna Dahlstrand, Véronique D'Hondt, Leslie M. Randall, Sophie Abadie-Lacourtoisie, Claudia Andreetta, Nerea Anzizar, Daiseuke Aoki, Maria Pilar Barretina-Ginesta, Marco Battista, Charlotte Bellier, Anne Gry Bentzen, Dominique Berton, Bertrand Billemont, Line Bjørge, Maria Bjurberg, Destin Black, Alessandra Bologna, Elena Ioana Braicu, Claudia Casanova, Radoslav Chekerov, Annick Chevalier, Juan Fernando Cueva, Bastian Czogalla, Nicolas Delanoy, Dominik Denschlag, Oscar Derke, Michael Eichbaum, Takayuki Enomoto, Carmen Esteban, Michel Fabbro, Tanja Fehm, Annamaria Ferrero, Markus Fleisch, Anne Floquet, Antonio Frassoldati, Lydia Gaba, Angiolo Gadducci, Yolanda García, Elena Geuna, Eva Guerra, Lars Hanker, Anne Claire Hardy-Bessard, Philipp Harter, Kosei Hasegawa, Kristina Hellman, Ana Herrero, Felix Hilpert, Dionyssios Katsaros, Matthias Koegel, Anthoula Koliadi, Jean Emmanuel Kurtz, Bjoern Lampe, Andrea Alberto Lissoni, Alain Lortholary, Giorgia Mangili, Laura Mansi, Frederik Marmé, Cara Mathews, William Mina, Shinichiro Minobe, Katherine Moxley, Shoji Nagao, Ornella Nicoletto, Koji Nishino, Hiroshi Nishio, Michaela Onstad, Beatriz Pardo, Carmela Pisano, Andrés Poveda, Julia Radosa, Leslie M. Randall, Andrés Redondo, Debra Richardson

The Lancet 403 ( 10421 ) 31 - 43 2024.1

Publishing type：Research paper (scientific journal)

Background: The GOG240 trial established bevacizumab with chemotherapy as standard first-line therapy for metastatic or recurrent cervical cancer. In the BEATcc trial (ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030), we aimed to evaluate the addition of an immune checkpoint inhibitor to this standard backbone. Methods: In this investigator-initiated, randomised, open-label, phase 3 trial, patients from 92 sites in Europe, Japan, and the USA with metastatic (stage IVB), persistent, or recurrent cervical cancer that was measurable, previously untreated, and not amenable to curative surgery or radiation were randomly assigned 1:1 to receive standard therapy (cisplatin 50 mg/m2 or carboplatin area under the curve of 5, paclitaxel 175 mg/m2, and bevacizumab 15 mg/kg, all on day 1 of every 3-week cycle) with or without atezolizumab 1200 mg. Treatment was continued until disease progression, unacceptable toxicity, patient withdrawal, or death. Stratification factors were previous concomitant chemoradiation (yes vs no), histology (squamous cell carcinoma vs adenocarcinoma including adenosquamous carcinoma), and platinum backbone (cisplatin vs carboplatin). Dual primary endpoints were investigator-assessed progression-free survival according to Response Evaluation Criteria in Solid Tumours version 1.1 and overall survival analysed in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT03556839, and is ongoing. Findings: Between Oct 8, 2018, and Aug 20, 2021, 410 of 519 patients assessed for eligibility were enrolled. Median progression-free survival was 13·7 months (95% CI 12·3–16·6) with atezolizumab and 10·4 months (9·7–11·7) with standard therapy (hazard ratio [HR]=0·62 [95% CI 0·49–0·78]; p<0·0001); at the interim overall survival analysis, median overall survival was 32·1 months (95% CI 25·3–36·8) versus 22·8 months (20·3–28·0), respectively (HR 0·68 [95% CI 0·52–0·88]; p=0·0046). Grade 3 or worse adverse events occurred in 79% of patients in the experimental group and in 75% of patients in the standard group. Grade 1–2 diarrhoea, arthralgia, pyrexia, and rash were increased with atezolizumab. Interpretation: Adding atezolizumab to a standard bevacizumab plus platinum regimen for metastatic, persistent, or recurrent cervical cancer significantly improves progression-free and overall survival and should be considered as a new first-line therapy option. Funding: F Hoffmann-La Roche.

DOI： 10.1016/S0140-6736(23)02405-4

Scopus

PubMed

researchmap

Niraparib in Japanese patients with platinum-sensitive recurrent ovarian cancer: final results of a multicenter phase 2 study

Hiroaki Itamochi, Nobuhiro Takeshima, Junzo Hamanishi, Kosei Hasegawa, Motoki Matsuura, Kiyonori Miura, Shoji Nagao, Hidekatsu Nakai, Naotake Tanaka, Hideki Tokunaga, Shin Nishio, Hidemichi Watari, Yoshihito Yokoyama, Yoichi Kase, Shuuji Sumino, Ai Kato, Ajit Suri, Toshiaki Yasuoka, Kazuhiro Takehara

Journal of Gynecologic Oncology 2024

Not taking sick leave for gynecologic cancer treatment is negatively associated with returning to the same workplace. Reviewed International journal

Keiichiro Nakamura, Hirofumi Matsuoka, Kotaro Kubo, Shinsuke Shirakawa, Naoyuki Ida, Junko Haraga, Chikako Ogawa, Kazuhiro Okamoto, Shoji Nagao, Hisashi Masuyama

Japanese journal of clinical oncology 2023.11

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: Gynecologic cancers are one of the most common types of malignancies in working-age women. We aimed to determine the factors that impede women from returning to the same workplace after treatment for such cancers. METHODS: A questionnaire-based survey was conducted on 194 women who underwent treatment for gynecologic cancer at the Okayama University (≥1 year after cancer treatment and <65 years of age). We performed a logistic regression analysis to determine the relationship between returning to the same workplace and not taking sick leave. RESULTS: The median age at diagnosis was 49.0 years, and the median time from cancer treatment to questionnaire completion was 3.8 years. Not returning to the same workplace was positively associated with not being regularly employed (P = 0.018), short work time per day (P = 0.023), low personal income (P = 0.004), not taking sick leave (P < 0.001), advanced cancer stage (P = 0.018) and long treatment time (P = 0.032). Interestingly, not taking sick leave was strongly associated with not returning to the same workplace in the multivariable analysis (P < 0.001). CONCLUSIONS: Not taking sick leave likely was negatively associated with returning to the same workplace after the treatment for gynecologic cancer. Therefore, we suggest that steps be taken to formally introduce a sick leave system over and above the paid leave system in Japan.

DOI： 10.1093/jjco/hyad159

PubMed

researchmap

【婦人科悪性腫瘍手術-トラブルシューティングとその予防法-】準広汎子宮全摘術

依田尚之, 長尾昌二, 増山寿

産婦人科の実際 72 ( 12 ) 1276 - 1284 2023.11

子宮体癌卵巣転移が多彩な組織像を呈した1例

花谷智美, 原賀順子, 大石恵一, 白河伸介, 谷佳紀, 杉原花子, 入江恭平, 依田尚之, 松岡敬典, 小川千加子, 中村圭一郎, 長尾昌二, 増山寿

現代産婦人科 72 ( Suppl. ) S59 - S60 2023.9

　 PREV - NEXT 　

< NAGAO Shoji >

Papers - NAGAO Shoji